iCarbonX
iCarbonX is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at iCarbonX.
iCarbonX is a company.
Key people at iCarbonX.
Key people at iCarbonX.
iCarbonX is a Shenzhen, China-based biotechnology company founded in 2015 that builds an AI-driven platform integrating multi-omics data, biological research, and machine intelligence to enable personalized health management, disease prevention, diagnosis, and treatment.[1][2][3][8] It serves individuals, biopharmaceutical firms, and healthcare providers by digitizing biological, behavioral, genetic, and environmental data to deliver predictive health insights, optimized recommendations, and tools for next-generation diagnostics, vaccines, and biomedicine.[1][2][4][5] With $199.8 million in funding (last raise $45 million about 9 years ago), 59-100 employees, and $8.8 million revenue, iCarbonX focuses on precision medicine, showing growth through its multi-omics lab and data analysis platform refocused since 2019.[2][3][6]
The company solves core problems in healthcare by combining diverse data sources—like genomics, proteomics, metabolomics, lifestyle, and medical records—with AI for holistic, individualized analysis, shifting from reactive treatment to proactive prevention.[1][4][5][6] This empowers users to monitor health, track risks for chronic diseases or cancer, and make data-backed choices, accelerating innovations in biotech and telemedicine.[3][5]
iCarbonX was founded in 2015 by Jun Wang, a leading genomics scientist who played a pivotal role in scaling genetic applications globally, including through the Human Genome Project and BGI (formerly Beijing Genomics Institute).[8] Wang assembled a team of top partners to extend beyond genomics into broader AI-powered health data ecosystems, driven by a vision to digitize life and enable people to "live longer and healthier" by preventing gradual decline through early interventions.[5][8]
The idea emerged from Wang's expertise in big data and genomics, evolving into a platform that integrates biological, behavioral, psychological, and environmental data for AI-driven insights.[5][6] Early traction came from building data partnerships and models, with a 2019 refocus on multi-omics labs to support biopharma R&D; by then, it had raised significant Series A-II funding, marking pivotal growth in precision health.[1][3]
iCarbonX rides the precision medicine and digital health wave, fueled by exploding multi-omics data, AI advancements, and post-pandemic demand for predictive, preventive care amid aging populations and chronic disease burdens.[1][3][4][5] Timing aligns with China's biotech boom and global shifts to data-driven healthcare, where market forces like falling sequencing costs and AI scalability favor integrated platforms over fragmented tools.[2][3]
It influences the ecosystem by empowering biopharma innovation, bridging research-to-clinic gaps, and fostering a networked health model that learns from aggregated user experiences—pioneering "virtual human" insights akin to competitors like Freenome or Twin Health, but with a China-centric scale.[3][5] This positions it as a key enabler in telemedicine, wearables, and big data biotech, potentially reshaping global health equity through ethical data use.[2][7]
iCarbonX is poised to expand its multi-omics-AI platform into advanced human modeling and global partnerships, targeting 10-20 year horizons of data ecosystems, predictive twins, and swift disease defeat.[1][5][8] Trends like AI-biotech convergence, real-world evidence from wearables, and regulatory tailwinds for precision therapies will propel growth, especially in Asia's massive health markets. Its influence may evolve from R&D enabler to consumer-facing health OS, amplifying impact if it scales ethically amid data privacy scrutiny—ultimately fulfilling its mission to let individuals drive their health destiny.[2][5][7] This builds on its foundational promise: turning life's carbon essence into actionable intelligence for longer, healthier lives.[8]
